Engineering herpes simplex virus vectors for CNS applications

Experimental Neurology

Volumn 159, Issue 1, 1999, Pages 34-46

  Wolfe, D ^a   Goins, W F ^a   Yamada, M ^a   Moriuchi, S ^a   Krisky, D M ^a   Oligino, T J ^a   Marconi, P C ^a   Fink, D J ^a   Glorioso, J C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BIOMEDICAL ENGINEERING; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRUS REPLICATION;

EID: 0032829989     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7158     Document Type: Article

References (99)

1. Barba D., Hardin J., Ray J., Gage F. H. Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79:1993;729-735.
2. Bi W. L., Parysek L. M., Warnick R., Stambrook P. J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HCV Tk retroviral gene therapy. Hum. Gene Ther. 4:1993;725-731.
3. Bloom D. C., Stevens J. G., Hill J. M., Tran R. K. Mutagenesis of a cAMP response element within the latency-associated transcript promoter of HSV-1 reduces adrenergic reactivation. Virology. 236:1997;202-207.
4. Cao G., Kuriyama S., Du P., Sakamoto T., Kong X., Masui K., Qi Z. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor α gene transfer. Gastroenterology. 11:1997;270-278.
5. Caruso M., Panis Y., Gagandeep S., Houssin D., Salzmann J. L., Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA. 90:1993;7024-7028.
6. Cedarbaum J. M., Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J. Neurol. Sci. 152:1997;S1-S9.
7. Chen L., Ashe S., Brady W., Hellstrom I., Hellstrom K. E., Ledbetter J. A., McGowan P., Linsley P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1992;1093-1102.
8. Chen X., Schmidt M. C., Goins W. F., Glorioso J. C. Two herpes simplex virus type-1 latency active promoters differ in their contribution to latency-associated transcript expression during lytic and latent infection. J. Virol. 69:1995;7899-7908.
9. Choi-Lundberg D., Lin Q., Chang Y.-N., Chiang Y.-L., Hay C., Mohajeri H., Davidson B., Bohn M. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 275:1996;838-841.
10. Colombo B. M., Benedetti S., Ottolenghi S., Mora M., Pollo B., Poli G., Finocchiaro G. The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6:1995;763-772.
11. Culver K., Ram Z., Walbridge S., Ishii H., Oldfield E., Blaese R. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
12. Deatly A. M., Spivack J. G., Lavi E., O'Boyle D., Fraser N. W. Latent herpes simplex virus type 1 transcripts in peripheral and central nervous systems tissues of mice map to similar regions of the viral genome. J. Virol. 62:1988;749-756.
13. DeLuca N. A., McCarthy A. M., Schaffer P. A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol. 56:1985;558-570.
14. DeLuca N. A., Schaffer P. A. Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol. Cell. Biol. 5:1985;1997-2008.
15. Devi-Rao G. B., Goddart S. A., Hecht L. M., Rochford R., Rice M. K., Wagner E. K. Relationship between polyadenylated and nonpolyadenylated HSV type 1 latency-associated transcripts. J. Gen. Virol. 65:1991;2179-2190.
16. Dobson A. T., Sederati F., Devi-Rao G., Flanagan W. M., Farrell M. J., Stevens J. G., Wagner E. K., Feldman L. T. Identification of the latency-associated transcript promoter by expression of rabbit β-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus. J. Virol. 63:1989;3844-3851.
17. Ezzeddine Z. D., Martuza R. L., Platika D., Short M. P., Malick A., Choi B., Breakefield X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3:1991;608-614.
18. Farrell M. J., Dobson A. T., Feldman L. T. Herpes simplex virus latency-associated transcript is a stable intron. Proc. Natl. Acad. Sci. USA. 88:1991;790-794.
19. Fink D. J., Ramakrishnan R., Marconi P., Goins W. F., Holland T. C., Glorioso J. C. Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin. Neurosci. 3:1996;1-8.
20. Finke S., Trojaneck B., Moller P., Schadendorf D., Neubauer A., Huhn D., Schmidt-Wolf I. G. Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. Cancer Gene Ther. 4:1997;260-268.
21. Fraser N. W., Block T. M., Spivack J. G. The latency-associated transcripts of herpes simplex virus: RNA in search of a function. Virology. 191:1992;1-8.
22. Freeman S. M., Whartenby K. A., Freeman J. L., Abboud C. N., Marrogi A. J. In situ use of suicide genes for cancer therapy. Semin. Oncol. 23:1996;31-45.
23. Freeman S. M., Zwiebel J. A. Gene therapy of cancer. Cancer Invest. 11:1993;676-688.
24. French S. W., Schmidt M. C., Glorioso J. C. Involvement of an HMG protein in the transcriptional activity of the herpes simplex virus latency active promoter 2. Mol. Cell. Biol. 16:1996;5393-5399.
25. Fuller A. O., Lee W. C. Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration. J. Virol. 66:1992;5002-5012.
26. Goins W. F., Lee K. A., Cavalcoli J. D., O'Malley M. E., DeKosky S. T., Fink D. J., Glorioso J. C. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglia neurons from peroxide toxicity. J. Virol. 73:1999;519-532.
27. L flanking repeats. J. Virol. 68:1994;2239-2252.
28. Gruenheid S., Gatzke L., Meadows H., Tufaro F. Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans. J. Virol. 67:1993;93-100.
29. Han S. K., Brody S. L., Crystal R. G. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am. J. Respir. Cell. Mol. Biol. 11:1994;270-278.
30. Henderson R. A., Finn O. J. Human tumor antigens are ready to fly. Adv. Immunol. 62:1996;217-256.
31. Herold B., Visalli R., Susmarski N., Brandt C., Spear P. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulfate and glycoprotein B. J. Gen. Virol. 75:1994;1211-1222.
32. Herrlinger U., Kramm C. M., Johnston K. M., Louis D. N., Finkelstein D., Reznikoff G., Dranoff G., Breakefield X. O., Yu J. S. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther. 4:1997;345-352.
33. Homa F. L., Brown J. C. Capsid assembly and DNA packaging in herpes simplex virus. Rev. Med. Virol. 7:1997;107-122.
34. Honess R., Roizman B. Regulation of herpes simplex virus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 14:1974;8-19.
35. Huber B. E., Richards C. A., Krenitsky T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA. 88:1991;8039-8043.
36. Ishiyama T., Mitsumoto H., Pioro E. P., Klinkosz B. Genetic transfer of the wobbler gene to a C57BL/6J × NZB hybrid stock: Natural history of the motor neuron disease and response to CNTF and BDNF cotreatment. Exp. Neurol. 148:1997;247-255.
37. Johnson P., Wang M., Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J. Virol. 68:1994;6347-6362.
38. Johnson P. A., Miyanohara A., Levine F., Cahill T., Friedmann T. Cytotoxicity of a replication-defective mutant herpes simplex virus type 1. J. Virol. 66:1992;2952-2965.
39. Kang W., Wilson M. A., Bender M. A., Glorioso J. C., Wilson S. P. Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res. 792:1998;133-135.
40. Kato K., Yoshida J., Mizuno M., Sugita K., Emi N. Retroviral transfer of herpes simplex thymidine kinase into glioma cells: Targeting of gancyclovir cytotoxic effect. Neurol. Med. Chir. (Tokyo). 34:1994;339-344.
41. Katsanis E., Xu Z., Bausero M. A., Dancisak B. B., Gorden K. B., Davis G., Gray G. S., Orchard P. J., Blazar B. R. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther. 2:1995;39-46.
42. Kenny J. I., Krebs F. C., Hartle H. T., Gartner A. E., Chatton B., Leiden J. M., Hoeffler J. P., Weber P. C., Wigdahl B. Identification of a second ATF/CREB-like element in the herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) promoter. Virology. 200:1994;220-235.
43. Kolluri R., Torrey T. A., Kinniburgh A. J. A CT promoter element binding protein: Definition of a double-strand and a novel single-strand DNA binding motif. Nucleic Acids Res. 20:1992;111-116.
44. Krisky D. M., Marconi P. C., Oligino T. J., Rouse R. J. D., Fink D. J., Cohen J. B., Watkins S. C., Glorioso J. C. Development of herpes simplex virus replication defective multigene vectors for combination gene therapy applications. Gene Ther. 5:1998;1517-1530.
45. Krisky D. M., Wolfe D., Goins W. F., Marconi P. C., Ramakrishnan R., Mata M., Rouse R. J. D., Fink D. J., Glorioso J. C. Deletion of multiple immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5:1998;1593-1603.
46. Laquerre S., Anderson D. B., Stolze D. B., Glorioso J. C. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor bearing cells. J. Virol. 72:1998;9683-9697.
47. Laquerre S., Argnani R., Anderson D. B., Zucchini S., Manservigi R., Glorioso J. C. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C which differ in their contribution to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:1998;6119-6130.
48. Laquerre S., Argnani R., Zucchini S., Manservigi R., Glorioso J. C. Herpes simplex virus type 1 glycoprotein B requires a cysteine residue at position 633 for folding, processing and incorporation into mature infectious virus particles. J. Virol. 72:1998;4940-4949.
49. Lindsay R. M. Therapeutic potential of the neurotrophins and neurotrophin-CNF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found. Symp. 196:1996;39-48.
50. Lokensgard J. R., Bloom D. C., Dobson A. T., Feldman L. T. Long-term promoter activity during herpes simplex virus latency. J. Virol. 68:1994;7148-7158.
51. Lokensgard J. R., Feldman L. T., Berthomme H. The latency-associated promoter of herpes simplex virus type 1 requires a region downstream of the transcription start site for long-term expression during latency. J. Virol. 71:1997;6714-6719.
52. Marconi P., Krisky D., Oligino T., Poliani P. L., Ramakrishnan R., Goins W. F., Fink D., Glorioso J. C. Replication-defective HSV vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;11319-11320.
53. Margolis T. P., Bloom D. C., Dobson A. T., Feldman L. T., Stevens J. G. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. Virology. 197:1993;585-592.
54. McGuire D., Ross M. A., Petajan J. H., Parry G. J., Miller R. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. J. Neurol. Sci. 152:1997;S18-S22.
55. Mester J. C., Pitha P., Glorioso J. C. Anti-viral activity of herpes simplex virus vectors expressing alpha-interferon. Gene Ther. 3:1995;187-196.
56. Mettenleiter T. C. Initiation and spread of A-herpesvirus infections. Trends Microbiol. 2:1994;2-3.
57. Mitchell W. J., Lirette R. P., Fraser N. W. Mapping of low abundance latency-associated RNA in the trigeminal ganglia of mice latently infected with herpes simplex virus type 1. J. Gen. Virol. 71:1990;125-132.
58. Montgomory R. I., Warner M. S., Lum B. J., Spear P. G. Herpes simplex virus 1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 87:1996;427-436.
59. Moolten F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281.
60. Moolten F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:1994;279-287.
61. Moriuchi S., Oligino T., Krisky D., Marconi P., Fink D., Cohen J., Glorioso J. C. Enhanced tumor-cell killing in the presence of ganciclovir by HSV-1 vector-directed co-expression of human TNF-α and HSV thymidine kinase. Cancer Res. 58:1998;5731-5737.
62. Nicola A. V., Peng C., Lou H., Cohen G. H., Eisenberg R. J. Antigenic structure of soluble herpes simplex virus (HSV) glycoprotein D correlates with inhibition of HSV infection. J. Virol. 71:1997;2940-2946.
63. Oligino T., Poliani P. L., Marconi P., Bender M. A., Schmidt M. C., Fink D. J., Glorioso J. C. In vivo transgene activation from an HSV-based gene vector by GAL4:VP16. Gene Ther. 3:1996;892-899.
64. Oligino T., Poliani P. L., Wang Y., Tsai S. Y., O'Malley B. W., Glorioso J. C. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther. 5:1998;491-496.
65. Ostensen M. E., Thiele D. L., Lipsky P. E. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2. J. Biol. Res. Mod. 8:1987;53-61.
66. Owen-Schaub L. B., Gutterman J. U., Grimm E. A. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 48:1988;788-792.
67. Pecher G., Finn O. J. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl. Acad. Sci. USA. 93:1996;1699-1704.
68. Pfizenmaier K., Pfizenmaier K., Scheurich P., Schluter C., Kronke M. Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells. J. Immunol. 138:1987;975-980.
69. Plaetinck G., Declercq W., Tavernier J., Jabholz M., Fiers W. Recombinant tumor necrosis factor can induce interleukin 2 receptor expression and cytolytic activity in a rat x mouse T cell hybrid. Eur. J. Immunol. 17:1987;1835-1838.
70. Postel E. H., Mango S. E., Flint S. J. A nuclease-hypersensitive element of the human c-myc promoter interacts with a transcription initiation factor. Mol. Cell. Biol. 9:1989;5123-5133.
71. Ram Z., Culver K. W., Walbridge S., Blaese R. M., Oldfield E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 46:1986;5276-5281.
72. Ranges G. E., Figari I. S., Espevik T., Palladino M. A. Jr. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med. 166:1987;991-998.
73. Rasty S., Goins W. F., Glorioso J. C. Site-Specific Integration of Multigenic Shuttle Plasmids into the Herpes Simplex Virus Type 1 (HSV-1) Genome Using a Cell-Free Cre-Lox Recombination System. 1995;Academic Press, San Diego.
74. Roizman B., Sears A. Herpes simplex viruses and their replication. Fields B. N., Knipe D. M., Howley P. M., Chanock R. M., Hirsch M. S., Melnick J. L., Monath T. P., Roizman B. Fields Virology. 1996;2231-2295 Lippincott-Raven, Philadelphia.
75. Rothlein R., Czajkowski M., O'Neill M. M., Marlin S. D., Merluzzi V. J. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J. Immunol. 141:1988;1665-1669.
76. Sadowski I., Ma J., Triezenberg S., Ptashne M. GAL4/VP16 is an unusually potent transcriptional activator. Nature. 335:1988;563-564.
77. Sagot Y., Aebischer P., Kato A. C., Schmalbruch H., Baetge E., Tan S. A. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Eur. J. Neurosci. 7:1995;1313-1322.
78. Saito H., Kouhara H., Kasayama S., Kishimoto T., Sato B. Characterization of the promoter region of the murine fibroblast growth factor receptor 1 gene. Biochem. Biophys. Res. Commun. 183:1992;688-693.
79. Samaniego L., Wu N., DeLuca N. The herpes simplex virus immediate-early protein ICPO affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71:1997;4614-4625.
80. Samaniego L. A., Neiderhiser L., DeLuca N. A. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72:1998;3307-3320.
81. Sawtell N. M. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 71:1997;5423-5431.
82. Sawtell N. M., Thompson R. L. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66:1992;2150-2156.
83. Sawtell N. M., Thompson R. L. Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J. Virol. 66:1992;2157-2169.
84. Schmidt W., Steinlein P., Buschle M., Schweighoffer T., Herbst E., Mechtler K., Kirlappos H., Birnstiel M. L. Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines. Proc. Natl. Acad. Sci. USA. 93:1996;9759-9763.
85. Soares M. K., Hwang D.-Y., Schmidt M. C., Fink D. J., Glorioso J. C. Cis-acting elements involved in transcriptional regulation of the herpes simplex virus type-1 latency-associated promoter 1 (LAP1) in vitro and in vivo. J. Virol. 70:1996;5384-5394.
86. Spear P. Membrane fusion induced by herpes simplex virus. Bentz J. Viral Fusion Mechanisms. 1993;201-232 CRC Press, Boca Raton.
87. Spear P. G. Entry of alphaherpesviruses into cells. Semin. Virol. 4:1993;167-180.
88. Stevens J. G., Wagner E. K., Devi-Rao G. B., Cook M. L., Feldman L. T. RNA complementary to a herpesviruses α gene mRNA is prominent in latently infected neurons. Science. 255:1987;1056-1059.
89. Tomac A., Linquist E., Lin L.-F., Ogren S., Young D., Hoffer B., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
90. Touraine R. L., Vahanian N., Ramsey W. J., Blaese R. M. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9:1998;2385-2391.
91. Wagner E. K., Devi-Rao G., Feldman L. T., Dobson A. T., Zhang Y., Elanagan W. F., Stevens T. Physical characterization of the herpes simplex virus latency-associated transcript in neurons. J. Virol. 62:1988;1194-1202.
92. Wang K., Pesniacak L., Straus S. E. Mutations in the 5′ end of the herpes simplex virus type 2 latency-associated transcript (LAT) promoter affect LAT expression in vivo but not the rate of spontaneous reactivation of genital herpes. J. Virol. 71:1997;7903-7910.
93. Whitbeck J. C., Peng C., Lou H., Xu R., Willis S. H., Ponce de Leon M., Peng T., Nicola A. V., Montgomery R. I., Warner M. S., Soulika A. M., Spruce L. A., Moore W. T., Lambris J. D., Spear P. G., Cohen G. H., Eisenberg R. J. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a mediator of HSV entry. J. Virol. 71:1997;6083-6093.
94. Whittemore S. R., Larkfors L., Ebendal T., Holets V. R., Ericsson A., Persson H. Increased beta-nerve growth factor messenger RNA and protein levels in neonatal rat hippocampus following specific cholinergic lesions. J. Neurosci. 7:1987;244-251.
95. Wilson S. P., Yeomans D. C., Bender M. A., Lu Y., Goins W. F., Glorioso J. C. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Natl. Acad. Sci. USA. 96:1999;3211-3216.
96. Wolfe J. H., Deshmane S. L., Fraser N. W. Herpesvirus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice. Nat. Genet. 1:1992;379-384.
97. Wu T.-T., Su Y.-H., Block T. M., Taylor J. M. Evidence that two latency-associated transcripts of herpes simplex virus type 1 are nonlinear. J. Virol. 70:1996;5962-5967.
98. Yamada M., Oligino T., Mata M., Goss J. R., Glorioso J. C., Fink D. J. HSV vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. USA. 96:1999;4078-4083.
99. Zabolotny J., Krummenacher C., Fraser N. W. The herpes simplex virus type 1 2.0-kilobase latency-associated transcript is a stable intron which branches at a guanosine. J. Virol. 71:1997;4199-4208.